drugset

drugset / Trial / NCT00166517

V260 Registration Study (V260-013)(COMPLETED)

NCT00166517 ↗

Phase 3 Completed 178 enrolled Merck Sharp & Dohme LLC

RandomizedParallel-groupDouble-blindPrevention

Summary

Immunogenicity and Safety of V260 in Healthy Infants in Korea

Timeline

Start: 2005-08
Primary completion: 2006-07
Completion: 2006-07

Publications

Results Kim DS, Lee TJ, Kang JH, Kim JH, Lee JH, Ma SH, Kim SY, Kim HM, Shin SM. Immunogenicity and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy infants in Korea. Pediatr Infect Dis J. 2008 Feb;27(2):177-8. doi: 10.1097/INF.0b013e31815aba79.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rotarix	Vaccine	—	Oral

Indications